1. Articles in category: Treatment

    1-24 of 217 1 2 3 4 5 6 7 8 9 »
    1. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      J Natl Compr Canc Netw. 2018 Jun;16(6):683-691

      Authors: Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W

      Abstract Metachronous neoplasms have rarely been reported in patients with neuroblastoma.

      Read Full Article
      Mentions: ALK
    2. Children with neuroblastoma have an elevated risk of long-term psychological difficulties

      A new study reveals that paediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.

      In addition, those who experience such impairment as they get older tend to require special education services and to not go on to...

      Read Full Article
      Mentions: Treatment
    3. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    4. Rigorous study finds widely used treatment for infection fails young cancer patients

      A treatment designed to reduce bloodstream infections due to central venous catheters that had worked well in lab studies and is commonly used around the world, but had not been rigorously tested, failed to protect young cancer patients from recurring or...

      Read Full Article
      Mentions: Treatment
    5. Rigorous study finds widely used treatment for infection fails young cancer patients

      Rigorous study finds widely used treatment for infection fails young cancer patients

      ( St. Jude Children's Research Hospital ) St. Jude Children's Research Hospital found ethanol-lock therapy failed to prevent new or recurring infections in cancer patients with central venous catheters and was associated with increased complications.

      Read Full Article
      Mentions: Treatment
    6. NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.

      Read Full Article
    7. Clinical significance of MYCN amplification in patients with high‐risk neuroblastoma

      Fifty‐one (38%) patients had MYCN amplified tumors, and the remaining 84 (62%) had nonamplified tumors. MYCN amplification was associated with abdominal primary site, less differentiated pathology, higher levels of lactate dehydrogenase and neuron‐specific enolase (NSE), lower vanillylmandelic acid level, and larger primary tumor volume at diagnosis. MYCN amplification was associated with a better early response (faster reduction of primary tumor volume and NSE level).

      Read Full Article
      Mentions: MYCN NSE
    8. Cancer Treatment and End-of-Life Care.

      Cancer Treatment and End-of-Life Care.

      J Palliat Med. 2018 May 16;:

      Authors: Sinha S, Matharu JK, Jacob J, Palat G, Brun E, Wiebe T, Segerlantz M

      Abstract AIM: To study to what extent tumor-specific treatment (chemo- or radiotherapy) was given during the last 30 days in life and to examine how many of the patients were referred to a specialized palliative care unit (PCU), at a low-resource governmental hospital in India.

      Read Full Article
    9. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      BMC Cancer. 2018 May 11;18(1):560

      Authors: Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M

      Abstract BACKGROUND: Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal.

      Read Full Article
    10. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    11. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      Oncotarget. 2018 Apr 06;9(26):18160-18179

      Authors: Roth SA, Hald ØH, Fuchs S, Løkke C, Mikkola I, Flægstad T, Schulte J, Einvik C

      Abstract Neuroblastoma is the most common diagnosed tumor in infants and the second most common extracranial tumor of childhood. The survival rate of patients with high-risk neuroblastoma is still very low despite intensive multimodal treatments.

      Read Full Article
      Mentions: MYCN
    12. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Cancer Cell Int. 2018;18:63

      Authors: Aveic S, Pantile M, Polo P, Sidarovich V, De Mariano M, Quattrone A, Longo L, Tonini GP

      Abstract Background: A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation.

      Read Full Article
    13. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    14. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    15. [Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases].

      [Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases].

      Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):295-297

      Authors: Zhang WY, Zhang Y, Dong NN, Wang YC, Sheng GY, Xu XJ, Liu YF

      Read Full Article
    16. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma

      PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma

      The majority of high-risk neuroblastoma patients are refractory to, or relapse on, current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets. Here, we report that high PIM kinase expression is correlated with poor overall survival. Treatment of neuroblastoma cell lines with the pan-PIM inhibitors AZD1208 or PIM-447 suppressed proliferation through inhibition of mTOR signaling.

      Read Full Article
    17. Parent understanding of the risk of future limitations secondary to pediatric cancer treatment

      Parents and physicians may have different understandings of a child's risk of future limitations due to cancer or cancer treatment. We evaluated alignment between parent‐ and physician‐estimated risk of late effects. We surveyed 352 parents of children with cancer within 12 weeks of diagnosis, and the children's oncologists, at Dana‐Farber/Boston Children's Cancer and Blood Disorders Center and Children's Hospital of Philadelphia.

      Read Full Article
      Mentions: Treatment
    18. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    19. Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Korean J Pediatr. 2018 Feb;61(2):53-58

      Authors: Kim C, Choi YB, Lee JW, Yoo KH, Sung KW, Koo HH

      Abstract Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen.

      Read Full Article
    20. Study identifies two new biomarkers for common form of childhood cancer

      Study identifies two new biomarkers for common form of childhood cancer

      Two new biomarkers for a type of cancer in children called neuroblastoma have been identified in a study published in the journal Cancer Cell. The findings are expected to have immediate significance for disease prognosis, and eventually also for treatment. "There is a need for new methods of ...

      Read Full Article
    1-24 of 217 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Treatments in the News

    1. (1 articles) MIBG
    2. (1 articles) Relapse